"Study","Study.year","Analysis.name","Analysis.number","Subgroup.number","Experimental.cases","Experimental.N","Control.cases","Control.N","Experimental.mean","Experimental.SD","Control.mean","Control.SD","GIV.Mean","GIV.SE","Mean","CI.start","CI.end","Variance","Weight","analysis_key","dataset_name","exp_cases_gt_n","ctrl_cases_gt_n","exp_cases_lt0","ctrl_cases_lt0","exp_n_le0","ctrl_n_le0","exp_cases_nonint","ctrl_cases_nonint","exp_n_nonint","ctrl_n_nonint","double_zero","all_events","sparse_events","exp_sd_le0","ctrl_sd_le0","variance_negative","giv_se_negative","ci_inverted","ci_mismatch"
"Erken 2021",2021,"All-cause mortality",1,NA,0,7,0,8,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hsu 2018",2018,"All-cause mortality",1,NA,0,94,0,93,0,0,0,0,0,1.62656806934433,NA,NA,NA,2.64572368421053,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Jonas 2016",2016,"All-cause mortality",1,NA,0,120,0,60,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016a",2016,"All-cause mortality",1,NA,0,45,0,45,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016b",2016,"All-cause mortality",1,NA,0,52,0,50,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"POTENT study 2018",2018,"All-cause mortality",1,NA,0,81,0,81,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Pessoa 2008",2008,"All-cause mortality",1,NA,0,51,0,17,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Xie 2014",2014,"All-cause mortality",1,NA,0,146,0,72,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2005",2005,"All-cause mortality",1,NA,0,141,0,71,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2007",2007,"All-cause mortality",1,NA,0,116,0,29,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"De Man 2001",2001,"Proportion of people with serious adverse events",2,NA,5,34,0,8,0,0,0,0,0,1.42903311442935,2.828571,0.171859,46.554572,2.04213564213564,4.920053,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Erken 2021",2021,"Proportion of people with serious adverse events",2,NA,0,7,0,8,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hsu 2018",2018,"Proportion of people with serious adverse events",2,NA,12,94,7,93,0,0,0,0,0,0.452547776644735,1.696049,0.698601,4.117633,0.204799490146093,17.862793,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"Proportion of people with serious adverse events",2,NA,4,120,7,60,0,0,0,0,0,0.606512277581537,0.285714,0.08703,0.937986,0.367857142857143,14.48188,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2016",2016,"Proportion of people with serious adverse events",2,NA,0,40,0,40,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Li 2018",2018,"Proportion of people with serious adverse events",2,NA,0,23,0,26,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016a",2016,"Proportion of people with serious adverse events",2,NA,4,45,7,45,0,0,0,0,0,0.590264939169436,0.571429,0.179691,1.817173,0.348412698412698,14.81629,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people with serious adverse events",2,NA,4,52,2,50,0,0,0,0,0,0.843071308235093,1.923077,0.368445,10.037377,0.710769230769231,10.358706,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"POTENT study 2018",2018,"Proportion of people with serious adverse events",2,NA,1,81,7,81,0,0,0,0,0,1.05743358412359,0.142857,0.017981,1.134987,1.11816578483245,7.740471,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pessoa 2008",2008,"Proportion of people with serious adverse events",2,NA,1,51,0,17,0,0,0,0,0,1.6099317817474,1.038462,0.04426,24.365023,2.59188034188034,4.043453,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with serious adverse events",2,NA,5,146,1,72,0,0,0,0,0,1.08593821004817,2.465753,0.293493,20.71581,1.17926179604262,7.457782,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2005",2005,"Proportion of people with serious adverse events",2,NA,0,141,0,71,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2007",2007,"Proportion of people with serious adverse events",2,NA,0,116,1,29,0,0,0,0,0,1.62011923165745,0.08547,0.003571,2.045795,2.62478632478632,4.000786,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2013",2013,"Proportion of people with serious adverse events",2,NA,0,20,0,20,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Zeng 2021",2021,"Proportion of people with serious adverse events",2,NA,3,43,11,43,0,0,0,0,0,0.614598077067808,0.272727,0.081768,0.909652,0.377730796335447,14.317785,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Erken 2021",2021,"Mortality due to hepatitis B-related liver disease",3,NA,0,7,0,8,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hsu 2018",2018,"Mortality due to hepatitis B-related liver disease",3,NA,0,94,0,93,0,0,0,0,0,1.62656806934433,NA,NA,NA,2.64572368421053,NA,"3::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Jonas 2016",2016,"Mortality due to hepatitis B-related liver disease",3,NA,0,120,0,60,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016a",2016,"Mortality due to hepatitis B-related liver disease",3,NA,0,45,0,45,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016b",2016,"Mortality due to hepatitis B-related liver disease",3,NA,0,52,0,50,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"POTENT study 2018",2018,"Mortality due to hepatitis B-related liver disease",3,NA,0,81,0,81,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Pessoa 2008",2008,"Mortality due to hepatitis B-related liver disease",3,NA,0,51,0,17,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Xie 2014",2014,"Mortality due to hepatitis B-related liver disease",3,NA,0,146,0,72,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2005",2005,"Mortality due to hepatitis B-related liver disease",3,NA,0,141,0,71,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2007",2007,"Mortality due to hepatitis B-related liver disease",3,NA,0,116,0,29,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Erken 2021",2021,"Proportion of people with non-serious adverse events",4,NA,4,7,5,8,0,0,0,0,0,0.426781978465419,0.914286,0.3961,2.110374,0.182142857142857,0.796025,"4::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hsu 2018",2018,"Proportion of people with non-serious adverse events",4,NA,71,94,82,93,0,0,0,0,0,0.0699188311479074,0.856642,0.746938,0.982459,0.0048886429490895,29.6586,"4::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"Proportion of people with non-serious adverse events",4,NA,74,120,39,60,0,0,0,0,0,0.11897285049346,0.948718,0.751393,1.197863,0.0141545391545391,10.243379,"4::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016a",2016,"Proportion of people with non-serious adverse events",4,NA,10,45,8,45,0,0,0,0,0,0.424918292799399,1.25,0.543524,2.874757,0.180555555555555,0.803023,"4::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people with non-serious adverse events",4,NA,26,52,32,50,0,0,0,0,0,0.174587425752169,0.78125,0.554857,1.100016,0.0304807692307692,4.75678,"4::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"POTENT study 2018",2018,"Proportion of people with non-serious adverse events",4,NA,32,81,29,81,0,0,0,0,0,0.202586773003566,1.103448,0.741839,1.641323,0.0410414005959983,3.532782,"4::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pessoa 2008",2008,"Proportion of people with non-serious adverse events",4,NA,43,51,14,17,0,0,0,0,0,0.127487304595556,1.02381,0.797447,1.314427,0.0162530128330401,8.920826,"4::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with non-serious adverse events",4,NA,118,146,61,72,0,0,0,0,0,0.0642636361930697,0.953964,0.841067,1.082015,0.0041298149367552,35.108185,"4::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2005",2005,"Proportion of people with non-serious adverse events",4,NA,60,141,30,71,0,0,0,0,0,0.169774245326511,1.007092,0.722033,1.404693,0.0288232943761862,5.030317,"4::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2007",2007,"Proportion of people with non-serious adverse events",4,NA,38,116,7,29,0,0,0,0,0,0.355062648070682,1.357143,0.676699,2.721795,0.126069484054965,1.150082,"4::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"Proportion of people without histological improvement",5,NA,4,14,5,10,0,0,0,0,0,1.42275873718717,0.571429,0.203095,1.607774,2.02424242424242,58.021509,"5::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Tseng 2014",2014,"Proportion of people without histological improvement",5,NA,1,21,10,18,0,0,0,0,0,0,0.085714,0.012112,0.6066,0,41.978491,"5::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hsu 2018",2018,"Proportion of people with detectable HBsAg",6,NA,92,95,93,94,0,0,0,0,0,0.0213925156917134,0.978834,0.938642,1.020748,0.000457639727620206,0,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"Humayun 2018",2018,"Proportion of people with detectable HBsAg",6,NA,81,281,117,140,0,0,0,0,0,0.100951035434448,0.344922,0.283003,0.420388,0.0101911115552871,0,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"Proportion of people with detectable HBsAg",6,NA,118,120,59,60,0,0,0,0,0,0.0205846742398155,1,0.960458,1.04117,0.000423728813559326,0,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"Lim 2016a",2016,"Proportion of people with detectable HBsAg",6,NA,45,45,45,45,0,0,0,0,0,0.0218582498493988,1,0.958063,1.043772,0.000477783086478743,0,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"Lim 2016b",2016,"Proportion of people with detectable HBsAg",6,NA,52,52,50,50,0,0,0,0,0,0.0193347247221693,1,0.962814,1.038623,0.000373831580082067,0,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"Tangkijvanich 2016",2016,"Proportion of people with detectable HBsAg",6,NA,60,63,57,63,0,0,0,0,0,0.0496436760298602,1.052632,0.955036,1.160201,0.0024644945697577,0,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Tseng 2014",2014,"Proportion of people with detectable HBsAg",6,NA,21,21,18,18,0,0,0,0,0,0.0497951559804457,1,0.907015,1.102518,0.0024795575591169,0,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"Xie 2014",2014,"Proportion of people with detectable HBsAg",6,NA,140,146,69,72,0,0,0,0,0,0.0299567489668607,1.000596,0.943538,1.061104,0.000897406808663511,0,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"Cheng 2022",2022,"Proportion of people with detectable HBV-DNA",7,NA,1,33,0,19,0,0,0,0,0,1.60849460737697,1.764706,0.075426,41.28815,2.58725490196078,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"De Man 2001",2001,"Proportion of people with detectable HBV-DNA",7,NA,30,33,8,8,0,0,0,0,0,0.0995543482347084,0.949827,0.781454,1.154477,0.0099110682524375,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Humayun 2018",2018,"Proportion of people with detectable HBV-DNA",7,NA,81,281,117,140,0,0,0,0,0,0.100951035434448,0.344922,0.283003,0.420388,0.0101911115552871,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"Proportion of people with detectable HBV-DNA",7,NA,61,120,58,60,0,0,0,0,0,0.0929237425704305,0.525862,0.438304,0.630912,0.0086348219332956,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2016",2016,"Proportion of people with detectable HBV-DNA",7,NA,5,40,6,40,0,0,0,0,0,0,0.833333,0.27658,2.510826,0,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016a",2016,"Proportion of people with detectable HBV-DNA",7,NA,12,45,13,45,0,0,0,0,0,0.340311571669207,0.923077,0.473766,1.798505,0.115811965811966,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people with detectable HBV-DNA",7,NA,19,52,18,50,0,0,0,0,0,0.262595440311051,1.014957,0.606633,1.698124,0.0689563652721547,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Luetkemeyer 2011",2011,"Proportion of people with detectable HBV-DNA",7,NA,4,5,2,5,0,0,0,0,0,0.591607978309962,2,0.627267,6.376871,0.35,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pessoa 2008",2008,"Proportion of people with detectable HBV-DNA",7,NA,48,51,17,17,0,0,0,0,0,0.054544376956413,0.959341,0.862074,1.067582,0.0029750890575632,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"Tangkijvanich 2016",2016,"Proportion of people with detectable HBV-DNA",7,NA,59,63,56,63,0,0,0,0,0,0.0553196497953846,1.053571,0.945313,1.174227,0.0030602636534839,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Tseng 2014",2014,"Proportion of people with detectable HBV-DNA",7,NA,5,21,18,18,0,0,0,0,0,0.371195516500835,0.256757,0.124039,0.531477,0.137786111470322,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with detectable HBV-DNA",7,NA,96,146,43,72,0,0,0,0,0,0.113728961407255,1.100988,0.881,1.375906,0.0129342766627729,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2007",2007,"Proportion of people with detectable HBV-DNA",7,NA,107,116,29,29,0,0,0,0,0,0.0363357783155834,0.934376,0.870147,1.003346,0.0013202887857992,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"Zeng 2013",2013,"Proportion of people with detectable HBV-DNA",7,NA,0,20,14,20,0,0,0,0,0,1.40489409636573,0.034483,0.002197,0.541315,1.97372742200328,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2021",2021,"Proportion of people with detectable HBV-DNA",7,NA,5,43,16,43,0,0,0,0,0,0.464745491740397,0.3125,0.125678,0.777038,0.215988372093023,0,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"De Man 2001",2001,"Proportion of people with detectable HBeAg",8,NA,29,30,8,8,0,0,0,0,0,0.0904222775704916,1.00759,0.843949,1.202961,0.008176188281035,20.223518,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hsu 2018",2018,"Proportion of people with detectable HBeAg",8,NA,64,95,59,94,0,0,0,0,0,0.106815443080852,1.073327,0.870584,1.323286,0.0114095388805587,14.791166,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016a",2016,"Proportion of people with detectable HBeAg",8,NA,34,40,34,40,0,0,0,0,0,0.0939336436627724,1,0.831847,1.202144,0.0088235294117647,18.838332,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people with detectable HBeAg",8,NA,43,46,35,44,0,0,0,0,0,0.0857953341555448,1.175155,0.993267,1.390351,0.0073608393628616,22.287667,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Tseng 2014",2014,"Proportion of people with detectable HBeAg",8,NA,5,7,8,8,0,0,0,0,0,0.251702462305398,0.727941,0.444474,1.192191,0.0633541295306001,2.782712,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with detectable HBeAg",8,NA,100,146,46,72,0,0,0,0,0,0.104885301531723,1.072067,0.872857,1.316741,0.0110009264774005,15.310912,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2013",2013,"Proportion of people with detectable HBeAg",8,NA,14,20,17,20,0,0,0,0,0,0.173931310695734,0.823529,0.585637,1.158056,0.0302521008403361,5.765694,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hsu 2018",2018,"Proportion of people without HBeAg seroconversion",9,NA,67,95,60,94,0,0,0,0,0,0.102114769446838,1.104912,0.904498,1.349734,0.0104274261391809,7.699242,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"Proportion of people without HBeAg seroconversion",9,NA,91,120,54,60,0,0,0,0,0,0.067138137504175,0.842593,0.738702,0.961094,0.0045075295075295,13.291253,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2016",2016,"Proportion of people without HBeAg seroconversion",9,NA,21,25,20,23,0,0,0,0,0,1.40227794063045,0.966,0.765167,1.219545,1.96638342277877,6.091608,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016a",2016,"Proportion of people without HBeAg seroconversion",9,NA,37,40,39,40,0,0,0,0,0,0.0516531961068496,0.948718,0.857373,1.049795,0.0026680526680526,17.165147,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"Lim 2016b",2016,"Proportion of people without HBeAg seroconversion",9,NA,45,46,40,44,0,0,0,0,0,0.0524958956506781,1.076087,0.970874,1.192702,0.0027558190601668,16.929715,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pessoa 2008",2008,"Proportion of people without HBeAg seroconversion",9,NA,49,50,17,17,0,0,0,0,0,0.0467063020594318,0.998319,0.910989,1.094022,0.0021814786520668,18.599076,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"Tseng 2014",2014,"Proportion of people without HBeAg seroconversion",9,NA,5,7,8,8,0,0,0,0,0,0.251702462305398,0.727941,0.444474,1.192191,0.0633541295306001,1.616973,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people without HBeAg seroconversion",9,NA,109,146,50,72,0,0,0,0,0,0.0918482877860195,1.075068,0.897955,1.287116,0.0084361079692234,8.968495,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2013",2013,"Proportion of people without HBeAg seroconversion",9,NA,18,20,20,20,0,0,0,0,0,0.0871575964608758,0.902439,0.760728,1.070549,0.0075964466208368,9.638492,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hsu 2018",2018,"Proportion of people without normalisation of transaminases",10,NA,56,95,47,94,0,0,0,0,0,0.134048964710697,1.178947,0.90655,1.533194,0.0179691249400095,0,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"Proportion of people without normalisation of transaminases",10,NA,39,120,46,60,0,0,0,0,0,0.149599986884385,0.423913,0.316182,0.568351,0.0223801560758082,0,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2016",2016,"Proportion of people without normalisation of transaminases",10,NA,5,22,5,21,0,0,0,0,0,0,0.954545,0.322272,2.827289,0,0,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016a",2016,"Proportion of people without normalisation of transaminases",10,NA,6,13,7,15,0,0,0,0,0,0.407350053312953,0.989011,0.445107,2.197547,0.165934065934066,0,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people without normalisation of transaminases",10,NA,7,18,4,11,0,0,0,0,0,0.496379387558042,1.069444,0.40424,2.829288,0.246392496392496,0,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pessoa 2008",2008,"Proportion of people without normalisation of transaminases",10,NA,34,51,16,17,0,0,0,0,0,0.116105091003206,0.708333,0.564169,0.889337,0.0134803921568627,0,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Tangkijvanich 2016",2016,"Proportion of people without normalisation of transaminases",10,NA,18,63,16,63,0,0,0,0,0,0.293784825696501,1.125,0.632532,2.000887,0.0863095238095238,0,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people without normalisation of transaminases",10,NA,85,143,39,71,0,0,0,0,0,0.127781913775456,1.082123,0.842381,1.390096,0.016328217488118,0,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2007",2007,"Proportion of people without normalisation of transaminases",10,NA,19,59,15,16,0,0,0,0,0,0.199622376179782,0.343503,0.23228,0.507983,0.0398490930716622,0,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2013",2013,"Proportion of people without normalisation of transaminases",10,NA,2,20,10,20,0,0,0,0,0,0.707106781186547,0.2,0.05002,0.799688,0.5,0,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"Proportion of people with serious adverse events (risk of bias)",1,1,4,120,7,60,0,0,0,0,0,0.606512277581537,0.285714,0.08703,0.937986,0.367857142857143,100,"1::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pessoa 2008",2008,"Proportion of people with serious adverse events (risk of bias)",1,2,1,51,0,17,0,0,0,0,0,1.6099317817474,1.038462,0.04426,24.365023,2.59188034188034,50.263579,"1::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2007",2007,"Proportion of people with serious adverse events (risk of bias)",1,2,0,116,1,29,0,0,0,0,0,1.62011923165745,0.08547,0.003571,2.045795,2.62478632478632,49.736421,"1::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"De Man 2001",2001,"Proportion of people with serious adverse events (risk of bias)",1,3,5,34,0,8,0,0,0,0,0,1.42903311442935,2.828571,0.171859,46.554572,2.04213564213564,6.452876,"1::3","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Erken 2021",2021,"Proportion of people with serious adverse events (risk of bias)",1,3,0,7,0,8,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::3","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hsu 2018",2018,"Proportion of people with serious adverse events (risk of bias)",1,3,12,94,7,93,0,0,0,0,0,0.452547776644735,1.696049,0.698601,4.117633,0.204799490146093,22.820498,"1::3","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2016",2016,"Proportion of people with serious adverse events (risk of bias)",1,3,0,40,0,40,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::3","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Li 2018",2018,"Proportion of people with serious adverse events (risk of bias)",1,3,0,23,0,26,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::3","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016a",2016,"Proportion of people with serious adverse events (risk of bias)",1,3,4,45,7,45,0,0,0,0,0,0.590264939169436,0.571429,0.179691,1.817173,0.348412698412698,19.044675,"1::3","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people with serious adverse events (risk of bias)",1,3,4,52,2,50,0,0,0,0,0,0.843071308235093,1.923077,0.368445,10.037377,0.710769230769231,13.435654,"1::3","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"POTENT study 2018",2018,"Proportion of people with serious adverse events (risk of bias)",1,3,1,81,7,81,0,0,0,0,0,1.05743358412359,0.142857,0.017981,1.134987,1.11816578483245,10.093442,"1::3","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with serious adverse events (risk of bias)",1,3,5,146,1,72,0,0,0,0,0,1.08593821004817,2.465753,0.293493,20.71581,1.17926179604262,9.730445,"1::3","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2005",2005,"Proportion of people with serious adverse events (risk of bias)",1,3,0,141,0,71,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::3","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Zeng 2013",2013,"Proportion of people with serious adverse events (risk of bias)",1,3,0,20,0,20,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::3","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Zeng 2021",2021,"Proportion of people with serious adverse events (risk of bias)",1,3,3,43,11,43,0,0,0,0,0,0.614598077067808,0.272727,0.081768,0.909652,0.377730796335447,18.422411,"1::3","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"Proportion of people with serious adverse events (age of participants)",2,1,4,120,7,60,0,0,0,0,0,0.606512277581537,0.285714,0.08703,0.937986,0.367857142857143,100,"2::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"De Man 2001",2001,"Proportion of people with serious adverse events (age of participants)",2,2,5,34,0,8,0,0,0,0,0,1.42903311442935,2.828571,0.171859,46.554572,2.04213564213564,5.710515,"2::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Erken 2021",2021,"Proportion of people with serious adverse events (age of participants)",2,2,0,7,0,8,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hsu 2018",2018,"Proportion of people with serious adverse events (age of participants)",2,2,12,94,7,93,0,0,0,0,0,0.452547776644735,1.696049,0.698601,4.117633,0.204799490146093,21.018497,"2::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"Proportion of people with serious adverse events (age of participants)",2,2,0,23,0,26,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016a",2016,"Proportion of people with serious adverse events (age of participants)",2,2,4,45,7,45,0,0,0,0,0,0.590264939169436,0.571429,0.179691,1.817173,0.348412698412698,17.377394,"2::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people with serious adverse events (age of participants)",2,2,4,52,2,50,0,0,0,0,0,0.843071308235093,1.923077,0.368445,10.037377,0.710769230769231,12.092052,"2::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"POTENT study 2018",2018,"Proportion of people with serious adverse events (age of participants)",2,2,1,81,7,81,0,0,0,0,0,1.05743358412359,0.142857,0.017981,1.134987,1.11816578483245,9.010769,"2::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pessoa 2008",2008,"Proportion of people with serious adverse events (age of participants)",2,2,1,51,0,17,0,0,0,0,0,1.6099317817474,1.038462,0.04426,24.365023,2.59188034188034,4.68876,"2::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with serious adverse events (age of participants)",2,2,5,146,1,72,0,0,0,0,0,1.08593821004817,2.465753,0.293493,20.71581,1.17926179604262,8.679102,"2::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2005",2005,"Proportion of people with serious adverse events (age of participants)",2,2,0,141,0,71,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2007",2007,"Proportion of people with serious adverse events (age of participants)",2,2,0,116,1,29,0,0,0,0,0,1.62011923165745,0.08547,0.003571,2.045795,2.62478632478632,4.639076,"2::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2013",2013,"Proportion of people with serious adverse events (age of participants)",2,2,0,20,0,20,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Zeng 2021",2021,"Proportion of people with serious adverse events (age of participants)",2,2,3,43,11,43,0,0,0,0,0,0.614598077067808,0.272727,0.081768,0.909652,0.377730796335447,16.783835,"2::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"POTENT study 2018",2018,"Proportion of people with serious adverse events (history of treatment with other antivirals)",3,1,1,81,7,81,0,0,0,0,0,1.05743358412359,0.142857,0.017981,1.134987,1.11816578483245,50.374583,"3::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with serious adverse events (history of treatment with other antivirals)",3,1,5,146,1,72,0,0,0,0,0,1.08593821004817,2.465753,0.293493,20.71581,1.17926179604262,49.625417,"3::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2013",2013,"Proportion of people with serious adverse events (history of treatment with other antivirals)",3,1,0,20,0,20,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Li 2016",2016,"Proportion of people with serious adverse events (history of treatment with other antivirals)",3,2,0,40,0,40,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016a",2016,"Proportion of people with serious adverse events (history of treatment with other antivirals)",3,2,4,45,7,45,0,0,0,0,0,0.590264939169436,0.571429,0.179691,1.817173,0.348412698412698,50.587406,"3::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people with serious adverse events (history of treatment with other antivirals)",3,2,4,52,2,50,0,0,0,0,0,0.843071308235093,1.923077,0.368445,10.037377,0.710769230769231,35.56573,"3::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2007",2007,"Proportion of people with serious adverse events (history of treatment with other antivirals)",3,2,0,116,1,29,0,0,0,0,0,1.62011923165745,0.08547,0.003571,2.045795,2.62478632478632,13.846865,"3::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hsu 2018",2018,"Proportion of people with serious adverse events (co-interventions)",4,1,12,94,7,93,0,0,0,0,0,0.452547776644735,1.696049,0.698601,4.117633,0.204799490146093,23.607755,"4::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2016",2016,"Proportion of people with serious adverse events (co-interventions)",4,1,0,40,0,40,0,0,0,0,0,0,NA,NA,NA,0,NA,"4::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Li 2018",2018,"Proportion of people with serious adverse events (co-interventions)",4,1,0,23,0,26,0,0,0,0,0,0,NA,NA,NA,0,NA,"4::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016a",2016,"Proportion of people with serious adverse events (co-interventions)",4,1,4,45,7,45,0,0,0,0,0,0.590264939169436,0.571429,0.179691,1.817173,0.348412698412698,19.435238,"4::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people with serious adverse events (co-interventions)",4,1,4,52,2,50,0,0,0,0,0,0.843071308235093,1.923077,0.368445,10.037377,0.710769230769231,13.441164,"4::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"POTENT study 2018",2018,"Proportion of people with serious adverse events (co-interventions)",4,1,1,81,7,81,0,0,0,0,0,1.05743358412359,0.142857,0.017981,1.134987,1.11816578483245,9.980463,"4::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pessoa 2008",2008,"Proportion of people with serious adverse events (co-interventions)",4,1,1,51,0,17,0,0,0,0,0,1.6099317817474,1.038462,0.04426,24.365023,2.59188034188034,5.16755,"4::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with serious adverse events (co-interventions)",4,1,5,146,1,72,0,0,0,0,0,1.08593821004817,2.465753,0.293493,20.71581,1.17926179604262,9.609423,"4::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2013",2013,"Proportion of people with serious adverse events (co-interventions)",4,1,0,20,0,20,0,0,0,0,0,0,NA,NA,NA,0,NA,"4::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Zeng 2021",2021,"Proportion of people with serious adverse events (co-interventions)",4,1,3,43,11,43,0,0,0,0,0,0.614598077067808,0.272727,0.081768,0.909652,0.377730796335447,18.758406,"4::1","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"De Man 2001",2001,"Proportion of people with serious adverse events (co-interventions)",4,2,5,34,0,8,0,0,0,0,0,1.42903311442935,2.828571,0.171859,46.554572,2.04213564213564,23.348558,"4::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Erken 2021",2021,"Proportion of people with serious adverse events (co-interventions)",4,2,0,7,0,8,0,0,0,0,0,0,NA,NA,NA,0,NA,"4::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Jonas 2016",2016,"Proportion of people with serious adverse events (co-interventions)",4,2,4,120,7,60,0,0,0,0,0,0.606512277581537,0.285714,0.08703,0.937986,0.367857142857143,57.294051,"4::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2005",2005,"Proportion of people with serious adverse events (co-interventions)",4,2,0,141,0,71,0,0,0,0,0,0,NA,NA,NA,0,NA,"4::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2007",2007,"Proportion of people with serious adverse events (co-interventions)",4,2,0,116,1,29,0,0,0,0,0,1.62011923165745,0.08547,0.003571,2.045795,2.62478632478632,19.357391,"4::2","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Erken 2021",2021,"All-cause mortality (conducting the analyses according to the 'best-worst' case scenario)",1,NA,0,7,0,8,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hsu 2018",2018,"All-cause mortality (conducting the analyses according to the 'best-worst' case scenario)",1,NA,0,95,1,94,0,0,0,0,0,1.62653364617141,0.329861,0.013608,7.995919,2.64561170212766,100,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"All-cause mortality (conducting the analyses according to the 'best-worst' case scenario)",1,NA,0,120,0,60,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016a",2016,"All-cause mortality (conducting the analyses according to the 'best-worst' case scenario)",1,NA,0,45,0,45,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016b",2016,"All-cause mortality (conducting the analyses according to the 'best-worst' case scenario)",1,NA,0,52,0,50,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"POTENT study 2018",2018,"All-cause mortality (conducting the analyses according to the 'best-worst' case scenario)",1,NA,0,81,0,81,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Pessoa 2008",2008,"All-cause mortality (conducting the analyses according to the 'best-worst' case scenario)",1,NA,0,51,0,17,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Xie 2014",2014,"All-cause mortality (conducting the analyses according to the 'best-worst' case scenario)",1,NA,0,146,0,72,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2005",2005,"All-cause mortality (conducting the analyses according to the 'best-worst' case scenario)",1,NA,0,141,0,71,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2007",2007,"All-cause mortality (conducting the analyses according to the 'best-worst' case scenario)",1,NA,0,116,0,29,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Erken 2021",2021,"All-cause mortality (conducting the analyses according to the 'worst-best' case scenario)",2,NA,0,7,0,8,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hsu 2018",2018,"All-cause mortality (conducting the analyses according to the 'worst-best' case scenario)",2,NA,1,95,0,94,0,0,0,0,0,1.40671083963201,2.96875,0.122472,71.963268,1.97883538633819,100,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"All-cause mortality (conducting the analyses according to the 'worst-best' case scenario)",2,NA,0,120,0,60,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016a",2016,"All-cause mortality (conducting the analyses according to the 'worst-best' case scenario)",2,NA,0,45,0,45,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016b",2016,"All-cause mortality (conducting the analyses according to the 'worst-best' case scenario)",2,NA,0,52,0,50,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"POTENT study 2018",2018,"All-cause mortality (conducting the analyses according to the 'worst-best' case scenario)",2,NA,0,81,0,81,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Pessoa 2008",2008,"All-cause mortality (conducting the analyses according to the 'worst-best' case scenario)",2,NA,0,51,0,17,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Xie 2014",2014,"All-cause mortality (conducting the analyses according to the 'worst-best' case scenario)",2,NA,0,146,0,72,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2005",2005,"All-cause mortality (conducting the analyses according to the 'worst-best' case scenario)",2,NA,0,141,0,71,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2007",2007,"All-cause mortality (conducting the analyses according to the 'worst-best' case scenario)",2,NA,0,116,0,29,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Jonas 2016",2016,"Proportion of people with serious adverse events (restricting the analysis to trials at low risk of bias)",3,NA,4,120,7,60,0,0,0,0,0,0.606512277581537,0.285714,0.08703,0.937986,0.367857142857143,100,"3::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"POTENT study 2018",2018,"Proportion of people with serious adverse events (restricting the analysis to treatment-naive participants)",4,NA,1,81,7,81,0,0,0,0,0,1.05743358412359,0.142857,0.017981,1.134987,1.11816578483245,83.938394,"4::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with serious adverse events (restricting the analysis to treatment-naive participants)",4,NA,5,146,1,72,0,0,0,0,0,1.08593821004817,2.465753,0.293493,20.71581,1.17926179604262,16.061606,"4::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2013",2013,"Proportion of people with serious adverse events (restricting the analysis to treatment-naive participants)",4,NA,0,20,0,20,0,0,0,0,0,0,NA,NA,NA,0,NA,"4::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Li 2018",2018,"Proportion of people with serious adverse events (restricting the analysis to no industry-funded trials)",5,NA,0,23,0,26,0,0,0,0,0,0,NA,NA,NA,0,NA,"5::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Zeng 2013",2013,"Proportion of people with serious adverse events (restricting the analysis to no industry-funded trials)",5,NA,0,20,0,20,0,0,0,0,0,0,NA,NA,NA,0,NA,"5::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"De Man 2001",2001,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,5,34,0,8,0,0,0,0,0,1.42903311442935,2.828571,0.171859,46.554572,2.04213564213564,1.634199,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Erken 2021",2021,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,0,7,0,8,0,0,0,0,0,0,NA,NA,NA,0,NA,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hsu 2018",2018,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,12,94,7,93,0,0,0,0,0,0.452547776644735,1.696049,0.698601,4.117633,0.204799490146093,14.457855,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,4,120,7,60,0,0,0,0,0,0.606512277581537,0.285714,0.08703,0.937986,0.367857142857143,19.174602,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2016",2016,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,0,40,0,40,0,0,0,0,0,0,NA,NA,NA,0,NA,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Li 2018",2018,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,0,23,0,26,0,0,0,0,0,0,NA,NA,NA,0,NA,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016a",2016,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,4,45,7,45,0,0,0,0,0,0.590264939169436,0.571429,0.179691,1.817173,0.348412698412698,14.380952,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,4,52,2,50,0,0,0,0,0,0.843071308235093,1.923077,0.368445,10.037377,0.710769230769231,4.189409,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"POTENT study 2018",2018,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,1,81,7,81,0,0,0,0,0,1.05743358412359,0.142857,0.017981,1.134987,1.11816578483245,14.380952,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pessoa 2008",2008,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,1,51,0,17,0,0,0,0,0,1.6099317817474,1.038462,0.04426,24.365023,2.59188034188034,1.526142,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,5,146,1,72,0,0,0,0,0,1.08593821004817,2.465753,0.293493,20.71581,1.17926179604262,2.751794,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2005",2005,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,0,141,0,71,0,0,0,0,0,0,NA,NA,NA,0,NA,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2007",2007,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,0,116,1,29,0,0,0,0,0,1.62011923165745,0.08547,0.003571,2.045795,2.62478632478632,4.905456,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2013",2013,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,0,20,0,20,0,0,0,0,0,0,NA,NA,NA,0,NA,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Zeng 2021",2021,"Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",6,NA,3,43,11,43,0,0,0,0,0,0.614598077067808,0.272727,0.081768,0.909652,0.377730796335447,22.598639,"6::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"De Man 2001",2001,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,5,34,0,8,0,0,0,0,0,1.42903311442935,2.828571,0.171859,46.554572,2.04213564213564,1.634199,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Erken 2021",2021,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,0,7,0,8,0,0,0,0,0,0,NA,NA,NA,0,NA,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hsu 2018",2018,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,12,94,7,93,0,0,0,0,0,0.452547776644735,1.696049,0.698601,4.117633,0.204799490146093,14.457855,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,4,120,7,60,0,0,0,0,0,0.606512277581537,0.285714,0.08703,0.937986,0.367857142857143,19.174602,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2016",2016,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,0,40,0,40,0,0,0,0,0,0,NA,NA,NA,0,NA,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Li 2018",2018,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,0,23,0,26,0,0,0,0,0,0,NA,NA,NA,0,NA,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016a",2016,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,4,45,7,45,0,0,0,0,0,0.590264939169436,0.571429,0.179691,1.817173,0.348412698412698,14.380952,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,4,52,2,50,0,0,0,0,0,0.843071308235093,1.923077,0.368445,10.037377,0.710769230769231,4.189409,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"POTENT study 2018",2018,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,1,81,7,81,0,0,0,0,0,1.05743358412359,0.142857,0.017981,1.134987,1.11816578483245,14.380952,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pessoa 2008",2008,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,1,51,0,17,0,0,0,0,0,1.6099317817474,1.038462,0.04426,24.365023,2.59188034188034,1.526142,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,5,146,1,72,0,0,0,0,0,1.08593821004817,2.465753,0.293493,20.71581,1.17926179604262,2.751794,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2005",2005,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,0,141,0,71,0,0,0,0,0,0,NA,NA,NA,0,NA,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2007",2007,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,0,116,1,29,0,0,0,0,0,1.62011923165745,0.08547,0.003571,2.045795,2.62478632478632,4.905456,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2013",2013,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,0,20,0,20,0,0,0,0,0,0,NA,NA,NA,0,NA,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Zeng 2021",2021,"Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",7,NA,3,43,11,43,0,0,0,0,0,0.614598077067808,0.272727,0.081768,0.909652,0.377730796335447,22.598639,"7::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"De Man 2001",2001,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,5,34,0,8,0,0,0,0,0,1.42903311442935,2.828571,0.171859,46.554572,2.04213564213564,1.634199,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Erken 2021",2021,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,0,7,0,8,0,0,0,0,0,0,NA,NA,NA,0,NA,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hsu 2018",2018,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,12,94,7,93,0,0,0,0,0,0.452547776644735,1.696049,0.698601,4.117633,0.204799490146093,14.457855,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,4,120,7,60,0,0,0,0,0,0.606512277581537,0.285714,0.08703,0.937986,0.367857142857143,19.174602,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2016",2016,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,0,40,0,40,0,0,0,0,0,0,NA,NA,NA,0,NA,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Lim 2016a",2016,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,4,45,7,45,0,0,0,0,0,0.590264939169436,0.571429,0.179691,1.817173,0.348412698412698,14.380952,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,4,52,2,50,0,0,0,0,0,0.843071308235093,1.923077,0.368445,10.037377,0.710769230769231,4.189409,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"POTENT study 2018",2018,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,1,81,7,81,0,0,0,0,0,1.05743358412359,0.142857,0.017981,1.134987,1.11816578483245,14.380952,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pessoa 2008",2008,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,1,51,0,17,0,0,0,0,0,1.6099317817474,1.038462,0.04426,24.365023,2.59188034188034,1.526142,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,5,146,1,72,0,0,0,0,0,1.08593821004817,2.465753,0.293493,20.71581,1.17926179604262,2.751794,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2005",2005,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,0,141,0,71,0,0,0,0,0,0,NA,NA,NA,0,NA,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2007",2007,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,0,116,1,29,0,0,0,0,0,1.62011923165745,0.08547,0.003571,2.045795,2.62478632478632,4.905456,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2013",2013,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,0,20,0,20,0,0,0,0,0,0,NA,NA,NA,0,NA,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Zeng 2021",2021,"Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",8,NA,3,43,11,43,0,0,0,0,0,0.614598077067808,0.272727,0.081768,0.909652,0.377730796335447,22.598639,"8::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"De Man 2001",2001,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,5,34,0,8,0,0,0,0,0,1.42903311442935,2.828571,0.171859,46.554572,2.04213564213564,1.170259,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Erken 2021",2021,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,0,7,0,8,0,0,0,0,0,0,NA,NA,NA,0,NA,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hsu 2018",2018,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,12,95,8,94,0,0,0,0,0,0.432497779614898,1.484211,0.635682,3.46538,0.187054329371817,11.831733,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,4,120,7,60,0,0,0,0,0,0.606512277581537,0.285714,0.08703,0.937986,0.367857142857143,13.731037,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2016",2016,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,0,40,0,40,0,0,0,0,0,0,NA,NA,NA,0,NA,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Li 2018",2018,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,0,43,18,44,0,0,0,0,0,1.4121932390044,0.027641,0.001718,0.444709,1.99428974428974,26.91107,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016a",2016,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,4,45,7,45,0,0,0,0,0,0.590264939169436,0.571429,0.179691,1.817173,0.348412698412698,10.298278,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,4,52,2,50,0,0,0,0,0,0.843071308235093,1.923077,0.368445,10.037377,0.710769230769231,3.000059,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"POTENT study 2018",2018,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,1,81,7,81,0,0,0,0,0,1.05743358412359,0.142857,0.017981,1.134987,1.11816578483245,10.298278,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pessoa 2008",2008,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,1,51,0,17,0,0,0,0,0,1.6099317817474,1.038462,0.04426,24.365023,2.59188034188034,1.092878,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,5,146,1,72,0,0,0,0,0,1.08593821004817,2.465753,0.293493,20.71581,1.17926179604262,1.970575,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2005",2005,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,0,141,0,71,0,0,0,0,0,0,NA,NA,NA,0,NA,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2007",2007,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,0,116,1,29,0,0,0,0,0,1.62011923165745,0.08547,0.003571,2.045795,2.62478632478632,3.512824,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2013",2013,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,0,20,0,20,0,0,0,0,0,0,NA,NA,NA,0,NA,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Zeng 2021",2021,"Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",9,NA,3,43,11,43,0,0,0,0,0,0.614598077067808,0.272727,0.081768,0.909652,0.377730796335447,16.183008,"9::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"De Man 2001",2001,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,5,34,0,8,0,0,0,0,0,1.42903311442935,2.828571,0.171859,46.554572,2.04213564213564,1.617781,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Erken 2021",2021,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,0,7,0,8,0,0,0,0,0,0,NA,NA,NA,0,NA,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hsu 2018",2018,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,13,95,7,94,0,0,0,0,0,0.425156986607609,1.837594,0.767186,4.40148,0.180758463261263,14.311797,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Jonas 2016",2016,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,4,120,7,60,0,0,0,0,0,0.606512277581537,0.285714,0.08703,0.937986,0.367857142857143,18.981963,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2016",2016,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,0,40,0,40,0,0,0,0,0,0,NA,NA,NA,0,NA,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Li 2018",2018,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,20,43,0,44,0,0,0,0,0,0.244074719860117,41.931818,2.615836,672.166444,0.0595724688747944,1.005465,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016a",2016,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,4,45,7,45,0,0,0,0,0,0.590264939169436,0.571429,0.179691,1.817173,0.348412698412698,14.236472,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Lim 2016b",2016,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,4,52,2,50,0,0,0,0,0,0.843071308235093,1.923077,0.368445,10.037377,0.710769230769231,4.14732,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"POTENT study 2018",2018,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,1,81,7,81,0,0,0,0,0,1.05743358412359,0.142857,0.017981,1.134987,1.11816578483245,14.236472,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pessoa 2008",2008,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,1,51,0,17,0,0,0,0,0,1.6099317817474,1.038462,0.04426,24.365023,2.59188034188034,1.510809,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Xie 2014",2014,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,5,146,1,72,0,0,0,0,0,1.08593821004817,2.465753,0.293493,20.71581,1.17926179604262,2.724148,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Yao 2005",2005,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,0,141,0,71,0,0,0,0,0,0,NA,NA,NA,0,NA,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Yao 2007",2007,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,0,116,1,29,0,0,0,0,0,1.62011923165745,0.08547,0.003571,2.045795,2.62478632478632,4.856173,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zeng 2013",2013,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,0,20,0,20,0,0,0,0,0,0,NA,NA,NA,0,NA,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Zeng 2021",2021,"Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",10,NA,3,43,11,43,0,0,0,0,0,0.614598077067808,0.272727,0.081768,0.909652,0.377730796335447,22.371599,"10::overall","CD015536_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
